Literature DB >> 12036895

Immunologic effects of prophylactic donor lymphocyte infusion after allogeneic marrow transplantation for multiple myeloma.

Roberto Bellucci1, Edwin P Alyea, Edie Weller, Antoinette Chillemi, Ephraim Hochberg, Catherine J Wu, Christine Canning, Robert Schlossman, Robert J Soiffer, Kenneth C Anderson, Jerome Ritz.   

Abstract

Reconstitution of T-cell immunity after bone marrow transplantation (BMT) is often delayed, resulting in a prolonged period of immunodeficiency. Donor lymphocyte infusion (DLI) has been used to enhance graft-versus-leukemia activity after BMT, but the effects of DLI on immune reconstitution have not been established. We studied 9 patients with multiple myeloma who received myeloablative therapy and T-cell-depleted allogeneic BMT followed 6 months later by infusion of lymphocytes from the same donor. DLI consisted of 3 x 10(7) CD4(+) donor T cells per kilogram obtained after in vitro depletion of CD8(+) cells. Cell surface phenotype of peripheral lymphocytes, T-cell receptor (TCR) V beta repertoire, TCR rearrangement excision circles (TRECs), and hematopoietic chimerism were studied in the first 6 months after BMT and for 1 year after DLI. These studies were also performed in 7 patients who received similar myeloablative therapy and BMT but without DLI. Phenotypic reconstitution of T and natural killer cells was similar in both groups, but patients who received CD4(+) DLI developed increased numbers of CD20(+) B cells. TCR V beta repertoire complexity was decreased at 3 and 6 months after BMT but improved more rapidly in patients who received DLI (P =.01). CD4(+) DLI was also associated with increased numbers of TRECs in CD3(+) T cells (P <.001) and with conversion to complete donor hematopoiesis (P =.05). These results provide evidence that prophylactic infusion of CD4(+) donor lymphocytes 6 months after BMT enhances reconstitution of donor T cells and conversion to donor hematopoiesis as well as promoting antitumor immunity.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12036895     DOI: 10.1182/blood.v99.12.4610

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  21 in total

1.  A phase I study of CD25/regulatory T-cell-depleted donor lymphocyte infusion for relapse after allogeneic stem cell transplantation.

Authors:  Sarah Nikiforow; Haesook T Kim; Heather Daley; Carol Reynolds; Kyle Thomas Jones; Philippe Armand; Vincent T Ho; Edwin P Alyea; Corey S Cutler; Jerome Ritz; Joseph H Antin; Robert J Soiffer; John Koreth
Journal:  Haematologica       Date:  2016-06-27       Impact factor: 9.941

2.  Reversal of in situ T-cell exhaustion during effective human antileukemia responses to donor lymphocyte infusion.

Authors:  Pavan Bachireddy; Ursula Hainz; Michael Rooney; Olga Pozdnyakova; Julie Aldridge; Wandi Zhang; Xiaoyun Liao; F Stephen Hodi; Karyn O'Connell; W Nicholas Haining; Natalie R Goldstein; Christine M Canning; Robert J Soiffer; Jerome Ritz; Nir Hacohen; Edwin P Alyea; Haesook T Kim; Catherine J Wu
Journal:  Blood       Date:  2013-12-19       Impact factor: 22.113

3.  Lymphocyte expansion after unrelated cord blood allogeneic stem cell transplantation in adults.

Authors:  Y Le Bris; T Guillaume; A Ménard; M Illiaquer; J Martin; S Malard; A Duquesne; P Peterlin; C Debord; N Robillard; M Eveillard; S Wuillème; J Delaunay; M Mohty; A Garnier; P Moreau; M C Béné; P Chevallier
Journal:  Bone Marrow Transplant       Date:  2017-01-30       Impact factor: 5.483

Review 4.  Allogeneic stem cell transplantation for multiple myeloma: is there a future?

Authors:  B Dhakal; D H Vesole; P N Hari
Journal:  Bone Marrow Transplant       Date:  2016-01-04       Impact factor: 5.483

Review 5.  Current status of stem cell transplantation for multiple myeloma.

Authors:  Morie A Gertz; Martha Q Lacy; Angela Dispenzieri; Suzanne Hayman
Journal:  Curr Treat Options Oncol       Date:  2005-05

6.  National Cancer Institute's First International Workshop on the Biology, Prevention, and Treatment of Relapse after Allogeneic Hematopoietic Stem Cell Transplantation: summary and recommendations from the organizing committee.

Authors:  Michael R Bishop; Edwin P Alyea; Mitchell S Cairo; J H Frederik Falkenburg; Carl H June; Nicolaus Kröger; Richard F Little; Jeffrey S Miller; Steven Z Pavletic; David L Porter; Stanley R Riddell; Koen van Besien; Alan S Wayne; Daniel J Weisdorf; Roy S Wu; Sergio Giralt
Journal:  Biol Blood Marrow Transplant       Date:  2011-01-09       Impact factor: 5.742

7.  Early recovery of CD4 T cell receptor diversity after "lymphoablative" conditioning and autologous CD34 cell transplantation.

Authors:  Jan Storek; Zhao Zhao; Yiping Liu; Richard Nash; Peter McSweeney; David G Maloney
Journal:  Biol Blood Marrow Transplant       Date:  2008-12       Impact factor: 5.742

Review 8.  T cell immune reconstitution following lymphodepletion.

Authors:  Kirsten M Williams; Frances T Hakim; Ronald E Gress
Journal:  Semin Immunol       Date:  2007-11-19       Impact factor: 11.130

Review 9.  Immunotherapy for Multiple Myeloma, Past, Present, and Future: Monoclonal Antibodies, Vaccines, and Cellular Therapies.

Authors:  Rebecca Karp Leaf; Hearn Jay Cho; David Avigan
Journal:  Curr Hematol Malig Rep       Date:  2015-12       Impact factor: 3.952

Review 10.  Immune reconstitution and implications for immunotherapy following haematopoietic stem cell transplantation.

Authors:  Kirsten M Williams; Ronald E Gress
Journal:  Best Pract Res Clin Haematol       Date:  2008-09       Impact factor: 3.020

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.